American Association for the Study of Liver Diseases - United States
Virus targets
Hepatitis B
Hepatitis C
Type
Technical assistance
Setting
National
Other targets
HAV
Hepatitis A
Hepatitis D virus
Hepatitis E
Phase
Active
Health outcomes
Incidence
Mortality
Prevalence
WHO region
Region of the Americas
Target goal
Country
United States of America
Key interventions
Blood safety
Coinfection with HIV
Community mobilization
Harm reduction
HBV perinatal screening and prophylaxis
HBV testing and linkage to care
HCV testing and linkage to Care
HCV treatment
Hep B birth-dose vaccination
Hepatitis B Vaccination
Implementation of birth dose vaccination
Implementation of vaccination (general)
Injection safety and infection control
Linkage to care
Persons who inject drugs: HCV cure as prevention
Persons who inject drugs: Syringe service program(s)
Prevention mother-child transmission
Prophylaxis
Safer injection practices
Strategic data analysis
Testing
Screening and diagnosis
Treatment
Treatment (direct or referral)
Vaccination (general)
Target population
Adolescents (10 - 19 years of age)
Adults
Adults (> 19 years of age)
All ages
Birth cohorts of adults
Blood transfusion recipients
Children (> one year < 10 years of age)
Children 12-17
Children 5-11
Children Under 5
Household contact(s)
Incarcerated populations (current and former)
Infants (less than one year of age)
Men who have sex with men
Newborn (born in last 30 days)
Newborns
Occupations with possible exposure
Persons who inject drugs
Pregnant women
Sexual contact(s)
Performance target
Blood safety
Care cascade: Evidence of current infection
Care cascade: HBV diagnosis
Care cascade: HBV testing
Care cascade: HBV treatment
Care cascade: HCV diagnosis
Care cascade: HCV testing
Care cascade: HCV treatment
Care cascade: Other
Care cascade: Referred for treatment
Harm reduction (access to safe injection equipment for persons who inject drugs)
HBV prevention of mother to child transmission
Hepatitis B vaccination coverage
Injection safety
Vaccination coverage
Care cascade
Testing
Summary and objectives
AASLD's Mission: To advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care
AASLD's key activities include:
- Guideline development: AASLD develops evidence-based practice guidelines and practice guidances which are updated regularly by a committee of hepatology experts and include recommendations of preferred approaches to the diagnostic, therapeutic, and preventive aspects of care. https://www.hcvguidelines.org/
- Conferences: AASLD annually hosts The Liver Meeting®, which is the largest worldwide scientific conference on liver diseases. It also conducts several regional liver disease meetings that vary in topic and emphasis.
- Journals: AASLD also publishes three major scientific journals on liver disease: Hepatology, Liver Transplantation and Clinical Liver Disease.
- Clinical Liver Disease is a multimedia review journal. It is clinical in focus and blends text, audio, video, webinars and other multimedia into an interactive resource for all physicians and healthcare providers with liver disease patients
- Education: AASLD hosts both in-person and online continuing education opportunities for its members. Find out more about upcoming opportunities: https://www.aasld.org/calendar
- Awareness: AASLD promotes and participates in awareness campaigns to bring attention to liver disease. For example, Hepatitis Awareness Month is in May each year.
- Public policy: Bringing attention to key issues affecting the field of hepatology. Learn more about AASLD's public policy committee at: https://www.aasld.org/programs-initiatives/public-policy
Call to action to accelerate HCV elimination
In November 2019, the American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), Asian-Pacific Association for the Study of the Liver (APASL) and Latin American Association for the Study of the Liver (ALEH), in partnership with CHAI, announced a global call-to-action at the 2019 Liver Meeting in Boston to simplify hepatitis C testing and treatment.
Read more about the Call to Action here: https://www.globalhep.org/news/coalition-liver-associations-calls-simplifying-hepatitis-c-care
